Musculoskeletal manifestations of chronic renal failure

Current Opinion in Rheumatology

Volumn 15, Issue 1, 2003, Pages 48-54

  Bardin, Thomas ^a,b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SENSING RECEPTOR; FALECALCITRIOL; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARICALCITOL; SEVELAMER; VITAMIN D DERIVATIVE;

CALCIFICATION; CHRONIC KIDNEY FAILURE; DIALYSIS; DRUG MECHANISM; DRUG POTENCY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MUSCULOSKELETAL DISEASE; OXYGEN TRANSPORT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; REVIEW;

CLINICAL TRIALS; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCULOSKELETAL DISEASES; RENAL DIALYSIS;

EID: 0037215518     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200301000-00009     Document Type: Review

References (50)

1. Shiota E, Tsuchiya K, Yamaoka K, et al.: Spontaneous major tendon ruptures in patients receiving long-term hemodialysis. Clin Orthop Rel Res 2001, 394:236-242.
2. Ritter CS, Finch JL, Slatopolsky EA, et al.: Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 2001, 60:1737-1744.
3. Välimäki S, Farnebo F, Forsberg L, et al.: Heterogenous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int 2001, 60:1666-1675. In situ hybridization was performed in parathyroid glands of renal patients operated for refractory HPP to investigate the expression of calcium receptor (CaR), calcium sensing receptor (CAS), vitamin D receptor (VDR), and PTH mRNAs in these specimen. Results confirmed decreased expression of CaR, CAS, and VDR compared with normal glands. PTH mRNA was also decreased, suggesting that the great increase in the number of parathyroid cells, and not increased synthesis per cell, was responsible for the high levels of serum PTH in renal HPP. Interestingly, the expression of the four investigated genes was highly variable between different glands as well as within individual glands. Each nodule appeared to have its own profile of mRNA expression, suggesting that the rapid cell proliferation of parathyroid cells increased the risk of mutation, leading to the formation of monoclonal nodules, the clonal origin of each nodule being separate.
4. Gonzales EA, Lund RJ, McCartney JE, et al.: Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int 2002, 61:1322-1331.
5. Slatopolsky E, Finch J, Clay P, et al.: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58:753-761. This interesting study demonstrates that the "intact" PTH assay routinely used for measurement of serum PTH levels also reacts with 7-84 PTH fragment. This fragment is produced by uremic parathyroid gland and has an inhibitory effect on PTH activity. Thus, the "intact" PTH assay overestimates serum 1-84 PTH level and activity.
6. Nakanishi S, Kazama JJ, Shigematsu T, et al.: Comparison of intact PTH assay and whole PTH assay in long term dialysis patients. Am J Kidney Dis 2001, 38(suppl 1):S172-S174.
7. Picton ML, Moore PR, Mawer EB, et al.: Down-regulation of human PTH/PTHrP receptor mRNA in end-stage renal disease. Kidney Int 2000, 58:1440-1449.
8. Kazama JJ, Shigematsu T, Yano K, et al.: Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39:525-532. Serum osteoprotegerin levels were found elevated in renal failure patients, suggesting a new mechanism of skeletal resistance to PTH.
9. Haas M, Leko-Mohr Z, Roschger P, et al.: Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralizatlon in hemodialysis patients. Am J Kidney Dis 2002, 39:580-586.
10. Coen G, Ballanti, Balducci A, et al.: Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002, 17:233-238.
11. Schwarz U, Buzello M, Ritz E, et al.: Morphology of coronary artery atherosclerotic lesions in patients with end stage renal failure. Nephrol Dial Transpl 2000, 15:218-223.
12. Raggi P: Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transpl 2002, 17:332-335.
13. Goodman WG, Goldin J, Kuizon B, et al.: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483. This electron-beam computed tomography study did not detect significant cardiac calcification in 23 dialysis patients aged less than 20 years but demonstrated that 14 of 16 examined dialysis patients aged 20 to 30 years had coronary artery calcification, at an age at which coronary calcification was seldom observed in controls. Coronary artery calcification was associated with high phosphatemia, serum calcium × phosphorus product, and calcium intake. Rapid progression of calcification was demonstrated in 10 patients examined after a mean interval of 20 months and appeared associated with the same factors.
14. Guérin AP, London GM, Marchais SJ, et al.: Arterial stiffening and vascular calcifications in end stage renal disease. Nephrol Dial Transpl 2000, 15:1014-1021.
15. Block GA, Hulbert-Shearon TE, Levin NW, et al.: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. A national study. Am J Kidney Dis 1998, 131:607-617.
16. Ahmed S, O'Neil KD, Hood AF, et al.: Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001, 37:1267-1276. This case-control study shows association of CUA with white race, female gender, obesity, hyperphosphatemia, and elevated serum calcium × phosphorus product but not with HPP. Immunohistology demonstrates staining of calcified skin arterioles for osteopontin, suggesting that an active mechanism, which could involve local dedifferentiation of smooth muscle cells into osteoblast-like cells, is involved in media calcification.
17. Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 2002, 61:2210-2217.
18. Mazhar AR, Johnson RJ, Gillen D, et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001, 60:324-332. A case-control study showing an eight-fold increase of mortality risk in CUA patients, and an association of CUA with female gender, hyperphosphatemia, and high serum alkaline phosphatase activity but not with high levels of circulating PTH.
19. Goodman WG: Vascular calcification in renal failure. Lancet 2001, 358:1115-1116.
20. Llach F: The evolving pattern of calciphylaxis: therapeutic considerations. Nephrol Dial Transplant 2001, 16:448-451.
21. Dwyer KM, Francis DMA, Hill PA, et al.: Calcific uraemic arteriolopathy: local treatment and hyperbaric oxygen therapy. Nephrol Dial Transplant 2002, 17:1148-1149.
22. Martin KJ, Gonzales EA: Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001, 38:1430-1436.
23. Locatelli F, Cannata-Andia JB, Drüeke TB, et al.: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002, 17:723-731. A nice review of management of osteodystrophy summarizing the opinions of numerous experts in the field.
24. Malluche HH, Mawad H: Management of hyperphosphatemia of chronic kidney disease: Lessons from the past and future directions. Nephrol Dial Transplant 2002, 17:1170-1175.
25. Coladonato JA, Szcech LA, Friedman EA, et al.: Does calcium kill ESRD patients? The skeptic's perspective. Nephrol Dial Transplant 2002, 17:229-232.
26. Hergesell O, Riz E: Phosphate binders in uremia: Pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 2002, 17:14-17.
27. Amin N: The impact of improved phosphorus control: Use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002, 17:340-345.
28. Raggi P, Burke SK, Dillon MA, et al.: Sevelamer attenuates the progression of coronary and aortic calcification compared with calcium-based phosphate binders. J Am Soc Nephrol 2001, 12:A1232.
29. Behets GS, Dams S, Dammant PC, et al.: An assessment of the effects of lanthanum on bone in a chronic renal failure rat model. J Am Soc Nephrol 2001, 12:A3862.
30. Yang W-C, Yang C-S, Hou C-C, et al.: An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Transplant 2002, 17:265-270.
31. Akizawa T, Suzuki M, Akiba T, et al.: Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001, 38:S147-S151.
32. Goodman WG: Calcimimetic agents and secondary hyperparathyroidism: Treatment and prevention. Nephrol Dial Transplant 2002, 17:204-207.
33. Malberti F, Marcelli D, Conte F, et al.: Parathyroidectomy in patients on renal replacement therapy: An epidemiological study. J Am Soc Nephrol 2001, 1242-1248.
34. Tominaga Y, Uchida K, Haba T, et al.: More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001, 38(suppl 1):S168-S171. This Japanese study reports on a series of 1053 total PTx with forearm autograft in renal patients. Despite an impressive attempt to remove ectopic glands by intensive preoperative exploration and peroperative excisions, 1.5% of patients experienced recurrence due to supernumerary gland. Graft recurrence rate increased with follow-up to 8.1%, but patients were easily treated as no muscle infiltration was observed at the forearm. Graft recurrence was mainly observed after the nodular parathyroid gland was transplanted and should be limited by avoiding nodular gland transplantation after macroscopic and intraoperative histologic examination.
35. Yamamoto TY, Ozono K, Miyauchi A, et al.: Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001, 38(suppl 1):S161-S164.
36. Inaba M, Nagasue K, Okuno S, et al.: Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002, 39:1261-1269.
37. Qi Q, Mohier-Frugene MC, Geng Z, et al.: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995, 26:622-631.
38. Avram MM, Mittman N, Myint MM, et al.: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 Years of prospective observation. Am J Kidney Dis 2001, 38:1351-1357. This prospective study demonstrates increased mortality and correlation with low serum albumin of renal hypoparathyroidism.
39. Guh JY, Chen H-C, Chuang H-Y, et al.: Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002, 39:1245-1254.
40. Atsumi K, Kushida K, Yamamaki K, et al.: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999, 33:287-293.
41. Gal-Moscovici A, Popovtzer MM: Parathyroid hormone-independent osteoclastic resorptive bone disease: A new variant of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 2002, 17:620-624.
42. Limaye V, Frankham A, Disney A, et al.: Evaluation of hand function in patients undergoing long term haemodialysis. Ann Rheum Dis 2001, 60:278-280.
43. Sunday JM, Guille JT, Torg JS: Complications of joint arthroplasty in patients with end-stage renal disease on hemodialysis. Clin Orthop 2002, 397:350-355.
44. Chen NX, O'Neill, KD, Niwa T, et al.: Signal transduction of β2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts. Kidney Int 2002, 61:414-424.
45. Pepys MB, Herbert J, Hutchinson WL, et al.: Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254-259. This important work shows that depletion of the amyloid SAP can be obtained in animal amyloid models and systemic human amyloidoses, by using a small proline derivative. Although not mentioned in this article, this approach could be used in β2M amyloid.
46. Khajehdehi P, Mojerlou M, Behzadi S, et al.: A randomized, double blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001, 16:1448-1451.
47. Kunis CL, Markowitz GS, Liu-Jarin X, et al.: Painful myopathy and end-stage renal disease. Am J Kidney Dis 2001, 37:1098-1104.
48. Castaneda C, Gordon P, Uhlin K, et al.: Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Meal 2001, 135: 965-976. In patients with moderate renal failure, following a low-protein diet, progressive weight-lifting exercises improved muscular condition in a placebo-controlled, randomized study.
49. Sala E, Noyszewski EA, Campistol JM, et al.: Impaired muscle oxygen transfer in patients with chronic renal failure. Am J Physiol Regulatory Integrative Comp Physiol 2001, 280:R1240-R1248.
50. Cowper SE, Su LD, Bahwan J, et al.: Nephrogenic fibrosing dermopathy. Am J Dermopathol 2001, 23:383-393.